Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Factor VII - KM Biologics

Next Previous
Drug Profile

Factor VII - KM Biologics

Alternative Names: KD2-305

Latest Information Update: 12 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator KM Biologics
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant proteins
  • Mechanism of Action Factor VII replacements; Thrombin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Haemophilia

Most Recent Events

  • 12 Dec 2025 Factor VII is still Registered for Haemophilia in Japan (IV)
  • 09 Feb 2023 Registered for Haemophilia in Japan (IV) (Meiji Holdings pipeline, February 2023)
  • 14 Nov 2022 Preregistration for Haemophilia in Japan (IV) (Meiji Seika Pharma pipeline, November 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top